GlaxoSmithKline

$36.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.29 (-0.78%) Today
-$0.02 (-0.05%) As of 7:33 AM EST after-hours

Why Robinhood?

You can buy or sell GSK and other stocks, options, and ETFs commission-free!

About GSK

GlaxoSmithKline plc, also called GlaxoSmithKline, is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom. The listed name for GSK is GlaxoSmithKline plc.

CEO
Emma N. Walmsley
Employees
99,437
Headquarters
Middlesex, Greater London
Founded
1999
Market Cap
91.49B
Price-Earnings Ratio
11.38
Dividend Yield
5.38
Average Volume
6.84M
High Today
$36.93
Low Today
$36.48
Open Price
$36.91
Volume
5.74M
52 Week High
$48.25
52 Week Low
$31.43

Collections

GSK News

ReutersNov 19

Vectura's $89.7 mln inhaler patent win against GSK upheld

GlaxoSmithKline PLC has lost an appeal seeking to overturn an $89.7 million verdict a jury handed down after finding that the company’s Ellipta line of inhalers
BenzingaNov 18

Jon Najarian Says These 2 Vaccine Manufacturers Haven't Been Talked About Enough

On CNBC's "Fast Money Halftime Report," Jon Najarian discussed the current state of vaccines and said some companies haven't been getting enough attention. The
CNBCNov 18

Top Biden advisor could face ethics pressure as his brother lobbies for pharma firms

U.S. President-elect Joe Biden delivers remarks about the U.S. economy during a press briefing at the Queen Theater on November 16, 2020 in Wilmington, Delaware

GSK Earnings

$0.00
$0.29
$0.58
$0.87
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Available Feb 3

You May Also Like